230 related articles for article (PubMed ID: 21122522)
1. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
[TBL] [Abstract][Full Text] [Related]
2. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
[TBL] [Abstract][Full Text] [Related]
3. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
4. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?
Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR
Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study.
Breynaert C; Ferrante M; Fidder H; Van Steen K; Noman M; Ballet V; Vermeire S; Rutgeerts P; Van Assche G
Am J Gastroenterol; 2011 Apr; 106(4):778-85. PubMed ID: 21407184
[TBL] [Abstract][Full Text] [Related]
6. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study.
Lee TW; Singh R; Fedorak RN
Aliment Pharmacol Ther; 2011 Jul; 34(2):181-7. PubMed ID: 21615434
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.
Babouri A; Roblin X; Filippi J; Hébuterne X; Bigard MA; Peyrin-Biroulet L
J Crohns Colitis; 2014 Feb; 8(2):161-5. PubMed ID: 23994253
[TBL] [Abstract][Full Text] [Related]
8. A nurse-led accelerated procedure for infliximab infusion is well tolerated and effective in patients with inflammatory bowel disease.
Michielan A; Martinato M; Favarin A; Zanotto V; Caccaro R; Caruso A; Sturniolo GC; D'Incà R
Dig Liver Dis; 2015 May; 47(5):372-7. PubMed ID: 25708258
[TBL] [Abstract][Full Text] [Related]
9. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis: rapid infliximab infusions are safe.
Neef HC; Riebschleger MP; Adler J
Aliment Pharmacol Ther; 2013 Aug; 38(4):365-76. PubMed ID: 23815183
[TBL] [Abstract][Full Text] [Related]
11. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
[TBL] [Abstract][Full Text] [Related]
12. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062
[TBL] [Abstract][Full Text] [Related]
13. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.
Domènech E; Zabana Y; Mañosa M; Garcia-Planella E; Cabré E; Gassull MA
J Clin Gastroenterol; 2010 Jan; 44(1):34-7. PubMed ID: 19417683
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.
Babouri A; Buisson A; Bigard MA; Peyrin-Biroulet L
J Crohns Colitis; 2013 Mar; 7(2):129-33. PubMed ID: 22472090
[TBL] [Abstract][Full Text] [Related]
15. Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.
Ma D; Wong W; Aviado J; Rodriguez C; Wu H
Am J Gastroenterol; 2019 Feb; 114(2):352-354. PubMed ID: 30333541
[TBL] [Abstract][Full Text] [Related]
16. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
Duburque C; Lelong J; Iacob R; Seddik M; Desreumaux P; Fournier C; Wallaert B; Cortot A; Colombel JF
Aliment Pharmacol Ther; 2006 Sep; 24(5):851-8. PubMed ID: 16918890
[TBL] [Abstract][Full Text] [Related]
17. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
Bálint A; Rutka M; Végh Z; Kürti Z; Gecse KB; Banai J; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Patai Á; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Bor R; Milassin Á; Fábián A; Nagy F; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Lakatos PL; Molnár T; Farkas K
Expert Opin Drug Saf; 2017 Aug; 16(8):885-890. PubMed ID: 28504555
[TBL] [Abstract][Full Text] [Related]
18. Infliximab infusion time in patients with inflammatory bowel diseases: is longer really safer?
Belhassan M; Zeitoun JD; Lefevre JH; Charachon A; Amiot A; Le Baleur Y; Sobhani I; Delchier JC
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):189-92. PubMed ID: 23246140
[TBL] [Abstract][Full Text] [Related]
19. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
Qazi T; Shah B; El-Dib M; Farraye FA
Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
[TBL] [Abstract][Full Text] [Related]
20. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
